46 related articles for article (PubMed ID: 32695667)
21. Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia.
Jovanovska A; Martinova K; Kocheva S; Trajkova-Antevska Z; Coneska-Jovanova B; Panovska-Stavridis I; Stankovikj S; Trajkova S; Dimovski A
Open Access Maced J Med Sci; 2019 Sep; 7(17):2818-2823. PubMed ID: 31844443
[TBL] [Abstract][Full Text] [Related]
22. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
23. Approach to the Adult Acute Lymphoblastic Leukemia Patient.
Sas V; Moisoiu V; Teodorescu P; Tranca S; Pop L; Iluta S; Pasca S; Blag C; Man S; Roman A; Constantinescu C; Rus I; Buse M; Fetica B; Marian M; Selicean C; Berindan-Neagoe I; Petrushev B; Bumbea H; Tanase A; Zdrenghea M; Fuji S; Kitano S; Tomuleasa C;
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31390838
[TBL] [Abstract][Full Text] [Related]
24. Unusual extramedullary relapses in a case of common B-cell acute lymphoblastic leukemia. Case report and review of literature.
Sava CN; Ritli L; Balmoş AB; Iuhas AR; Marian P; Motorca MA; Lele LA; Straciuc O; Zaha DC; Jurcă MC; Niulaş L; Negruţ N
Rom J Morphol Embryol; 2019; 60(1):249-254. PubMed ID: 31263852
[TBL] [Abstract][Full Text] [Related]
25. A Single Institution's Experience with Cytogenetic and MRD Outcomes in Pediatric Acute Lymphoblastic Leukemia.
Amjad A; Wali RM; Anjum S; Mansoor R
J Coll Physicians Surg Pak; 2019 Jun; 29(6):549-552. PubMed ID: 31133155
[TBL] [Abstract][Full Text] [Related]
26. Bone relapse in T-lineage acute lymphoblastic leukemia in a child.
Meena JP; Ahad A; Gupta AK; Mallick S; Seth R
Oxf Med Case Reports; 2018 Oct; 2018(10):omx110. PubMed ID: 30263126
[TBL] [Abstract][Full Text] [Related]
27. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.
O'Connor D; Enshaei A; Bartram J; Hancock J; Harrison CJ; Hough R; Samarasinghe S; Schwab C; Vora A; Wade R; Moppett J; Moorman AV; Goulden N
J Clin Oncol; 2018 Jan; 36(1):34-43. PubMed ID: 29131699
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
29. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
[TBL] [Abstract][Full Text] [Related]
30. Childhood relapsed acute lymphoblastic leukemia: Biology and recent treatment progress.
Goto H
Pediatr Int; 2015 Dec; 57(6):1059-66. PubMed ID: 26455582
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.
van Dongen JJ; van der Velden VH; Brüggemann M; Orfao A
Blood; 2015 Jun; 125(26):3996-4009. PubMed ID: 25999452
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
33. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
34. Declining childhood and adolescent cancer mortality.
Smith MA; Altekruse SF; Adamson PC; Reaman GH; Seibel NL
Cancer; 2014 Aug; 120(16):2497-506. PubMed ID: 24853691
[TBL] [Abstract][Full Text] [Related]
35. Acute lymphoblastic leukaemia.
Inaba H; Greaves M; Mullighan CG
Lancet; 2013 Jun; 381(9881):1943-55. PubMed ID: 23523389
[TBL] [Abstract][Full Text] [Related]
36. Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment.
Bartram CR; Schrauder A; Köhler R; Schrappe M
Dtsch Arztebl Int; 2012 Oct; 109(40):652-8. PubMed ID: 23094001
[TBL] [Abstract][Full Text] [Related]
37. How I treat relapsed childhood acute lymphoblastic leukemia.
Locatelli F; Schrappe M; Bernardo ME; Rutella S
Blood; 2012 Oct; 120(14):2807-16. PubMed ID: 22896001
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
39. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes.
Lauten M; Matthias T; Stanulla M; Beger C; Welte K; Schrappe M
Leukemia; 2002 Aug; 16(8):1437-42. PubMed ID: 12145682
[TBL] [Abstract][Full Text] [Related]
40. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
Dördelmann M; Reiter A; Borkhardt A; Ludwig WD; Götz N; Viehmann S; Gadner H; Riehm H; Schrappe M
Blood; 1999 Aug; 94(4):1209-17. PubMed ID: 10438708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
